产前基于单核苷酸多态性的游离DNA筛查识别全基因组父源单亲二体
回顾性分析单一商业实验室2014年6月至2023年11月的游离DNA筛查结果,89例报告为双胎或三倍体且疑似全基因组父源单亲二体,排除12例重解释为三倍体后余77例,其中24例有随访信息,21例(87.5%)超声和/或病理符合完全性葡萄胎伴共存胎儿;胎儿游离DNA分数常极低(28例≤2%),葡萄胎游离DNA分数10-58%。
要点
- 基于SNP的游离DNA筛查可识别完全性葡萄胎伴共存胎儿,并有助于与三倍体鉴别。
- 胎儿游离DNA分数常极低(28例≤2%),葡萄胎游离DNA分数范围10-58%。
- 所有77例均显示等二体,未见明确的异二体区域证据。
核心结论
- 基于SNP的游离DNA筛查有助于识别完全性葡萄胎伴共存胎儿并与三倍体鉴别;早期发现对评估不良结局和妊娠滋养细胞肿瘤风险重要;部分阳性病例可能包含未识别的胎盘间叶发育不良或嵌合/奇美拉型全基因组父源单亲二体综合征;这些初步观察无法评估该检测的敏感度或阳性预测值。
研究设计与样本
- 回顾性研究,分析单一商业实验室2014年6月至2023年11月所有报告为双胎或三倍体且疑似全基因组父源单亲二体的游离DNA筛查结果,共审查5 699 009例检测;采用SNP等位基因相对比值的二维图(SNP图)识别和量化葡萄胎游离DNA分数与共存非葡萄胎妊娠胎儿游离DNA分数;审查检测转诊和随访信息包括超声表现、实验室检测和妊娠结局。
诊断标准与关键数值
- 89例报告为双胎或三倍体且疑似全基因组父源单亲二体,回顾SNP图排除12例重解释为伴额外父源染色体组的三倍体,余77例;77例中24例有随访妊娠信息,其中21例(87.5%)超声和/或病理符合完全性葡萄胎伴共存胎儿;胎儿游离DNA分数常极低,28例≤2%;葡萄胎游离DNA分数范围10-58%;胎儿性别男35例、女40例、不确定2例;无病例在全基因组父源单亲二体线上显示明确Y染色体证据;全部77例均为等二体,无一例显示明确异二体区域证据。
临床应用与阅片要点
- 基于SNP的游离DNA筛查可帮助识别完全性葡萄胎伴共存胎儿并区分其与三倍体;对于完全性葡萄胎伴共存胎儿,早期发现对评估不良结局和妊娠滋养细胞肿瘤风险重要;部分检测阳性病例可能包含未识别的胎盘间叶发育不良或嵌合/奇美拉型全基因组父源单亲二体综合征;这些初步观察无法评估该检测的敏感度或阳性预测值。
局限性
- 这些初步观察无法评估该检测的敏感度或阳性预测值。
- 部分检测阳性病例可能包含未识别的胎盘间叶发育不良或嵌合/奇美拉型全基因组父源单亲二体综合征。
- 77例中仅24例有随访妊娠信息可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Prenatal single-nucleotide polymorphism (SNP)-based cell-free DNA (cfDNA) screening can identify genome-wide paternal uniparental disomy (GW-UPDpat), including cases with complete hydatidiform mole with a coexisting fetus (CHMCF), those with placental mesenchymal dysplasia (PMD) and those with a mosaic/chimeric GW-UPDpat syndrome. Our objective was to review laboratory data and pregnancy outcome for SNP-based cfDNA screening tests with results compatible with GW-UPDpat and a normal cell line.
METHODS: This was a retrospective study of all cfDNA screening results from a single commercial laboratory between June 2014 and November 2023 that were reported as twins or triploidy, with apparent GW-UPDpat. Two-dimensional representations of the relative ratios of SNP alleles (SNP plots) were used to identify and quantify the proportion of cfDNA from the mole ('molar fraction') and that from the coexisting non-molar pregnancy ('fetal fraction'). Test referral and follow-up information, including ultrasound findings, laboratory testing and pregnancy outcome, were reviewed.
RESULTS: Of 5 699 009 tests reviewed, 89 were reported as twins or triploidy, with apparent GW-UPDpat. Retrospective review of SNP plots excluded 12 cases that were reinterpreted as triploidy with an extra set of paternal chromosomes. Of the remaining 77 cases, 24 had follow-up pregnancy information available, and of these, 21 (87.5%) had ultrasound and/or pathology findings that were consistent with CHMCF. The fetal cfDNA fraction was often very low (≤ 2% in 28 cases). The molar cfDNA fraction was in the range of 10-58%. Fetal sex was male in 35 cases, female in 40 cases and uncertain in two cases. No case showed clear evidence of a Y-chromosome in the GW-UPDpat line. All 77 cases had isodisomy; none showed clear evidence of regions of heterodisomy.
CONCLUSIONS: SNP-based cfDNA screening can help to identify CHMCF and distinguish between CHMCF and triploidy. For CHMCF, early detection is important for evaluating the risk of adverse outcome and gestational trophoblastic neoplasia. Some of our test-positive cases could have included unrecognized PMD or mosaic/chimeric GW-UPDpat syndrome. These preliminary observations do not allow assessment of the sensitivity or positive predictive value of this test. © 2025 Natera, Inc. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Benn P, Hashimoto K, Souter V, et al. Whole-genome paternal uniparental disomy identified through prenatal single-nucleotide polymorphism-based cell-free DNA screening. Ultrasound Obstet Gynecol. 2025. PMID: 41299888. doi:10.1002/uog.70144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。